UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

Respiratory medicine, 2013-10, Vol.107 (10), p.1538-1546

2013

Volltextzugriff (PDF)

Accuracy of the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (CKD Epidemiology Collaboration) Equations for Estimation of GFR in the Elderly

American journal of kidney diseases, 2013-01, Vol.61 (1), p.57-66

2013

Volltextzugriff (PDF)

External Validation of the Berlin Equations for Estimation of GFR in the Elderly

American journal of kidney diseases, 2014-05, Vol.63 (5), p.862-865

2014

Volltextzugriff (PDF)

The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

International journal of chronic obstructive pulmonary disease, 2019-01, Vol.14, p.2849-2861

2019

Volltextzugriff (PDF)

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis

Apoptosis (London), 2014-04, Vol.19 (4), p.629-642

2014

Volltextzugriff (PDF)

Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach

Cell death & disease, 2013-05, Vol.4 (5), p.e629-e629

2013

Volltextzugriff (PDF)

Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability

Translational psychiatry, 2013-10, Vol.3 (10), p.e317-e317

2013

Volltextzugriff (PDF)

Key Improvements to the Army's Suicide Prevention and Intervention Training: An Interagency Collaboration to Develop the New "ACE Base +1" Curriculum

Military medicine, 2024-08, Vol.189 (Supplement_3), p.357-365

2024

Volltextzugriff (PDF)

Symmetric dimethylarginine is a stronger predictor of mortality risk than asymmetric dimethylarginine among older people with kidney disease

Annals of clinical biochemistry, 2019-05, Vol.56 (3), p.367-374

2019

Volltextzugriff (PDF)

PP277. IMPACT試験 (COPD患者を対象としたFF / UMEC / VIのFF / VI及びUMEC / VIとの比較試験) における有効性及び安全性の結果 : 日本人部分集団解析

日本呼吸器学会誌, 2019-03, Vol.8 (suppl), p.221-221

2019

Volltextzugriff (PDF)

PP913. IMPACT試験のUMEC/VIに対するFF/UMEC/VIの欠損または打ち切りデータを含めた全死因死亡 (ACM) リスク低減

日本呼吸器学会誌, 2020-08, Vol.9 (suppl), p.322-322

2020

Volltextzugriff (PDF)

PRS3 HEALTHCARE RESOURCE UTILIZATION AND CHARACTERIZATION OF PATIENTS WITH MODERATE TO SEVERE COPD AND A HISTORY OF EXACERBATIONS: SUB-ANALYSIS OF ARGENTINIAN PATIENTS ENROLLED IN THE IMPACT STUDY

Value in health, 2019-05, Vol.22, p.S349-S349

2019

Volltextzugriff (PDF)

PP278. IMPACT試験における単一吸入器3剤併用療法と2剤併用療法での増悪および肺炎リスクの比較

日本呼吸器学会誌, 2019-03, Vol.8 (suppl), p.221-221

2019

Volltextzugriff (PDF)

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Impact Of Vilanterol, Fluticasone Furoate, Or Their Combination On Exacerbations In COPD Patients With Moderate Airflow Obstruction: The Summit Trial

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

B14 HIGH IMPACT LATE-BREAKING CLINICAL TRIALS: Fluticasone Furoate, Alone Or In Combination With Vilanterol, Decreases The Rate Of Fev1 Decline In Patients With Moderate Airflow Obstruction: Summit Study

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

B44 COPD: COMORBIDITIES: Reported Pneumonia Events In The Summit Trial

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Impact Of A Long-Acting Beta Agonist And An Inhaled Corticosteroid In COPD Patients With Moderate Airflow Obstruction And Cv Disease Or Risk: A Factorial Analysis Of The Summit Trial

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

PP274. 高リスクCOPD患者におけるLAMA / LABAとICS / LABAの比較 : IMPACT試験の肺機能および健康状態に関する事前設定解析

日本呼吸器学会誌, 2019-03, Vol.8 (suppl), p.221-221

2019

Volltextzugriff (PDF)

PP275. スクリーニング時に3剤併用療法を受けている患者の部分集団におけるIMPACT試験の解析

日本呼吸器学会誌, 2019-03, Vol.8 (suppl), p.221-221

2019

Volltextzugriff (PDF)

C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Effect Of Treatment Withdrawal On Outcomes In The Summit Study

American journal of respiratory and critical care medicine, 2017-01, Vol.195

2017

Volltextzugriff (PDF)

Effets du traitement FF/UMEC/VI versus FF/VI et UMEC/VI chez les patients BPCO réversibles et non réversibles : analyses de l’étude IMPACT

Revue des maladies respiratoires, 2019-01, Vol.36, p.A98-A98

2019

Volltextzugriff (PDF)

InforMing the PAthway of COPD Treatment (étude IMPACT) : triple thérapie en un inhalateur unique (Furoate de Fluticasone/Umeclidinium/Vilanterol) comparée à Furoate de Fluticasone/Vilanterol et Umeclidinium/Vilanterol chez les patients atteints de bronchopneumopathie chronique obstructive (BPCO) : analyse basée sur les traitements de la BPCO à l’inclusion

Revue des maladies respiratoires actualités, 2020-01, Vol.12 (1), p.191-192

2020

Volltextzugriff (PDF)

L’effet du retrait du traitement sur les résultats de l’étude SUMMIT

Revue des maladies respiratoires, 2018-01, Vol.35, p.A196-A197

2018

Volltextzugriff (PDF)

Les cas de pneumonies rapportés dans l’étude Summit

Revue des maladies respiratoires, 2017-01, Vol.34, p.A171-A171

2017

Volltextzugriff (PDF)

Impact du vilanterol, du furoate de fluticasone ou de leur association sur les exacerbations chez des patients atteints de BPCO avec une obstruction modérée des voies aériennes : étude Summit

Revue des maladies respiratoires, 2017-01, Vol.34, p.A173-A174

2017

Volltextzugriff (PDF)

1 – 25 von 1.090

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(909)
Mit Volltextzugriff
(816)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cryobiology
(31)
Physiotherapy
(22)
American Anthropologist
(21)
Journal Of Perinatology
(21)
Pediatrics
(20)
Proceedings Of The Society Of Antiquaries Of Scotland
(15)
Chest
(13)
Pediatric Research
(13)
Disability And Rehabilitation
(12)
The Journal Of Pediatrics
(12)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD

Accuracy of the MDRD (Modification of Diet in Renal Disease) Study and CKD-EPI (CKD Epidemiology Collaboration) Equations for Estimation of GFR in the Elderly

External Validation of the Berlin Equations for Estimation of GFR in the Elderly

The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population

Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis

Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach

Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability

Key Improvements to the Army's Suicide Prevention and Intervention Training: An Interagency Collaboration to Develop the New "ACE Base +1" Curriculum

Symmetric dimethylarginine is a stronger predictor of mortality risk than asymmetric dimethylarginine among older people with kidney disease

PP277. IMPACT試験 (COPD患者を対象としたFF / UMEC / VIのFF / VI及びUMEC / VIとの比較試験) における有効性及び安全性の結果 : 日本人部分集団解析

PP913. IMPACT試験のUMEC/VIに対するFF/UMEC/VIの欠損または打ち切りデータを含めた全死因死亡 (ACM) リスク低減

PRS3 HEALTHCARE RESOURCE UTILIZATION AND CHARACTERIZATION OF PATIENTS WITH MODERATE TO SEVERE COPD AND A HISTORY OF EXACERBATIONS: SUB-ANALYSIS OF ARGENTINIAN PATIENTS ENROLLED IN THE IMPACT STUDY

PP278. IMPACT試験における単一吸入器3剤併用療法と2剤併用療法での増悪および肺炎リスクの比較

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Impact Of Vilanterol, Fluticasone Furoate, Or Their Combination On Exacerbations In COPD Patients With Moderate Airflow Obstruction: The Summit Trial

B14 HIGH IMPACT LATE-BREAKING CLINICAL TRIALS: Fluticasone Furoate, Alone Or In Combination With Vilanterol, Decreases The Rate Of Fev1 Decline In Patients With Moderate Airflow Obstruction: Summit Study

B44 COPD: COMORBIDITIES: Reported Pneumonia Events In The Summit Trial

D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS: Impact Of A Long-Acting Beta Agonist And An Inhaled Corticosteroid In COPD Patients With Moderate Airflow Obstruction And Cv Disease Or Risk: A Factorial Analysis Of The Summit Trial

PP274. 高リスクCOPD患者におけるLAMA / LABAとICS / LABAの比較 : IMPACT試験の肺機能および健康状態に関する事前設定解析

PP275. スクリーニング時に3剤併用療法を受けている患者の部分集団におけるIMPACT試験の解析

C41 LONG ACTING BRONCHODILATOR THERAPY IN COPD II: Effect Of Treatment Withdrawal On Outcomes In The Summit Study

Effets du traitement FF/UMEC/VI versus FF/VI et UMEC/VI chez les patients BPCO réversibles et non réversibles : analyses de l’étude IMPACT

L’effet du retrait du traitement sur les résultats de l’étude SUMMIT

Les cas de pneumonies rapportés dans l’étude Summit

Impact du vilanterol, du furoate de fluticasone ou de leur association sur les exacerbations chez des patients atteints de BPCO avec une obstruction modérée des voies aériennes : étude Summit

Suchergebnisse filtern